当前位置: 首页 >> 检索结果
1429. A call for health R&D prioritisation and governance mechanisms in Africa.
作者: Mosoka Papa Fallah.;Nebiyu Dereje.;Elvis Temfack.;Dathan M Byonanebye.;Jacqueline Weyer.;Polydor Ngoy Mutombo.;Wayengera Misaki.;Eastman Candace.;Alhaji Njai.;Nathalie Strub-Wourgaft.;Nelson Sewankambo.;Adu-Sarkodie Yaw.;Placide Mbala-Kingebeni.;Dougbeh-Chris Nyan.;Birkneh Tilahun Tadesse.;Christof Vinnemeier.;Luis Sambo.;Isaac Adewole.;Raji Tajudeen.;Jean Kaseya.
来源: Lancet. 2025年405卷10482期889-890页 1435. Behavioural interventions to increase uptake of FIT colorectal screening in Scotland (TEMPO): a nationwide, eight-arm, factorial, randomised controlled trial.
作者: Kathryn A Robb.;Ben Young.;Marie K Murphy.;Patrycja Duklas.;Alex McConnachie.;Gareth J Hollands.;Colin McCowan.;Sara Macdonald.;Ronan E O'Carroll.;Rory C O'Connor.;Robert J C Steele.
来源: Lancet. 2025年405卷10484期1081-1092页
Uptake of colorectal cancer screening is suboptimal. The TEMPO trial evaluated the impact of two evidence-based, theory-informed, and co-designed behavioural interventions on uptake of faecal immunochemical test (FIT) colorectal screening.
1438. Safety and immunogenicity of a pentavalent meningococcal conjugate vaccine targeting serogroups A, C, W, Y, and X when co-administered with routine childhood vaccines at ages 9 months and 15 months in Mali: a single-centre, double-blind, randomised, controlled, phase 3, non-inferiority trial.
作者: Fatoumata Diallo.;Fadima C Haidara.;Milagritos D Tapia.;Clara P Dominguez Islas.;Mark R Alderson.;William P Hausdorff.;Lionel Martellet.;Nancy Hosken.;Dhananjay Kapse.;Prasad S Kulkarni.;Kelly Townsend-Payne.;Francesca Vanni.;Christine M Posavad.;Samba O Sow.;Karen L Kotloff.;Wilbur H Chen.; .
来源: Lancet. 2025年405卷10484期1069-1080页
Invasive meningococcal disease is a devastating public health problem for the African meningitis belt. We assessed the safety and immunogenicity of a pentavalent meningococcal conjugate vaccine targeting serogroups A, C, Y, W, and X (NmCV-5) relative to a licensed, quadrivalent meningococcal conjugate vaccine (MenACWY-TT) when co-administered with routine childhood vaccines at ages 9 months and 15 months.
1439. Pharmacokinetics and safety of once-yearly lenacapavir: a phase 1, open-label study.
作者: Vamshi Jogiraju.;Pallavi Pawar.;Jenna Yager.;John Ling.;Gong Shen.;Anna Chiu.;Emma Hughes.;Ramesh Palaparthy.;Christoph Carter.;Renu Singh.
来源: Lancet. 2025年405卷10485期1147-1154页
Long-acting antiretrovirals can address barriers to HIV pre-exposure prophylaxis (PrEP), such as stigma and adherence. In two phase 3 trials, twice-yearly subcutaneous lenacapavir was safe and highly efficacious for PrEP in diverse populations. Furthering long-acting PrEP efforts, this study assessed the pharmacokinetics and safety of two once-yearly intramuscular lenacapavir formulations.
|